Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1079 - Inhibition of LAP2α can suppress cell aggressiveness in breast cancer


17 Dec 2016


Poster lunch


Xiaofen Li


Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574


X. Li1, Y. Huang2, Y. Hu3

Author affiliations

  • 1 Medical Oncology, 2nd Affiliated Hospital of Zhejiang University University School of Medicine, 310009 - Hangzhou/CN
  • 2 Cancer Institute, 2nd Affiliated Hospital of Zhejiang University University School of Medicine, 310009 - Hangzhou/CN
  • 3 Surgical Oncology, 2nd Affiliated Hospital of Zhejiang University University School of Medicine, 310009 - Hangzhou/CN


Abstract 1079


Breast cancer is the most common malignancy in women worldwide. But to date, there is no good serum protein marker for breast cancer diagnosis and prognosis. We conducted this study to screen and identify specific protein markers of breast cancer.


Mass spectrometry was applied to screen and identify differential serum protein profiles between 63 breast cancer patients and 40 healthy controls. Immunohistochemistry (IHC) and western blot analysis were used as verification experiments. Biological functions of candidate protein marker were studied in vitro.


Two amino acid fragments with sizes of 3.9kDa and 5.6kDa, respectively, were detected as candidate markers. A combined diagnostic model composed of these two fragments was built, with a sensitivity of 82.3% and a specificity of 95.3%. The 5.6kDa fragment, which was up regulated in breast cancer, was an important segment of lamina-associated polypeptide 2 alpha (LAP2α). IHC and western blot experiments confirmed over expression of LAP2α in breast cancer tissues. An inhibition plasmid vector of LAP2α-small hairpin RNA (shRNA) was constructed and transfected into MCF-7 cells. CCK-8 experiments on transfected cells showed that inhibition of LAP2αcould not influent cell proliferation. Transwell and matrigel-transwell assays indicated that inhibition of LAP2α could significantly reduce cell migration and invasion abilities.


We built a diagnostic model for early detection of breast cancer with a satisfactory accuracy. LAP2αwas identified as a candidate serum protein marker, which was overexpressed in breast cancer. Inhibition of LAP2αcould suppress MCF-7 cell aggressiveness. Our study indicated that LAP2αcould be a potential serum biomarker and therapeutic target of breast cancer.

Clinical trial indentification


Legal entity responsible for the study

The Second Affiliated Hospital, Zhejiang University School of Medicine, China


Zhejiang Provincial Natural Science Foundation of China


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings